Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

NCT ID: NCT03817502

Last Updated: 2025-10-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-06

Study Completion Date

2026-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cariprazine 1.5 mg/d

Cariprazine capsules, oral administration, once daily.

Group Type EXPERIMENTAL

Cariprazine

Intervention Type DRUG

Cariprazine capsules, oral administration, once daily.

Cariprazine 4.5 mg/d

Cariprazine capsules, oral administration, once daily.

Group Type EXPERIMENTAL

Cariprazine

Intervention Type DRUG

Cariprazine capsules, oral administration, once daily.

Placebo

Matching placebo capsules, oral administration, once daily.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo capsules, oral administration, once daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cariprazine

Cariprazine capsules, oral administration, once daily.

Intervention Type DRUG

Placebo

Matching placebo capsules, oral administration, once daily.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-5 primary diagnosis of schizophrenia.
* Schizophrenia diagnosis confirmed by the K-SADS-PL administered at screening (Visit 1) by a trained clinician.
* PANSS score ≥ 70 and a score of ≥ 4 (moderate) on 2 or more of the 5 items on the positive subscale of the PANSS (delusions, conceptual disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution), at screening (Visit 1) and baseline (Visit 2).
* CGI-S scale score of ≥ 4 (moderately ill) at screening (Visit 1) and baseline (Visit 2).

Exclusion Criteria

* Current diagnosis of bipolar disorder, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition
* Diagnosis of intellectual disability (IQ \< 70).
* Participant has a history of meeting DSM-5 diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before Visit 1.
Minimum Eligible Age

13 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gedeon Richter Plc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ProScience Research Group

Culver City, California, United States

Site Status COMPLETED

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Site Status COMPLETED

Atlanta Behavioral Research, LLC

Atlanta, Georgia, United States

Site Status WITHDRAWN

Bloomfield Hills MI

Bloomfield Hills, Michigan, United States

Site Status WITHDRAWN

Precise Research Centers

Flowood, Mississippi, United States

Site Status WITHDRAWN

UB Department of Psychiatry

Buffalo, New York, United States

Site Status WITHDRAWN

Manhattan Behavioral Medicine PLLC

New York, New York, United States

Site Status WITHDRAWN

University of Cincinnati

Cincinnati, Ohio, United States

Site Status COMPLETED

Family Psychiatry of The Woodlands

The Woodlands, Texas, United States

Site Status COMPLETED

Clinic of Child Psychiatry St. Nikolas

Sofia, , Bulgaria

Site Status RECRUITING

MHAT Targovishte

Targovishte, , Bulgaria

Site Status RECRUITING

Centro de Investigaciones y Proyectos en Nerurociencia. CIPNA. IPS. SAS.

Barranquilla, , Colombia

Site Status SUSPENDED

E.S.E. Hospital Mental de Antioquia

Bello, , Colombia

Site Status SUSPENDED

Centro de Investigacion del Sitema Nervioso CISNE

Bogotá, , Colombia

Site Status SUSPENDED

Instituto Colombiano Sistema Nervioso Clinica Monserrat

Bogotá, , Colombia

Site Status SUSPENDED

Psynapsis Salud Mental SA

Pereira, , Colombia

Site Status SUSPENDED

Centro para la Medicina y de Asistencia Medica Especializada S.C.

Culiacán, , Mexico

Site Status SUSPENDED

Instituto de Investigacion Clinica AC

Durango, , Mexico

Site Status SUSPENDED

Consultorio de Medicina Especializada del Sector Privado

Guadalajara, , Mexico

Site Status WITHDRAWN

Consultorio Medico En Psiquiatria de Niños y Adolescentes Hospital Aranda de la Parra

Guanajuato City, , Mexico

Site Status SUSPENDED

Medical Care and Research S.A. de C.V.

Mérida, , Mexico

Site Status ACTIVE_NOT_RECRUITING

Iecsi S.C.

Monterrey, , Mexico

Site Status SUSPENDED

CIT Neuropsique

Monterrey, , Mexico

Site Status SUSPENDED

Instituto de Informacion e Investigacion en Salud Mental AC

Monterrey, , Mexico

Site Status SUSPENDED

BLIND Investigaciones SC

San Luis Potosí City, , Mexico

Site Status SUSPENDED

Socola Psychiatric Institute Iasi

Iași, , Romania

Site Status WITHDRAWN

Spitalul Clinic de Urgenta Pentru Copii Louis Turcanu Clinica de Psihiatrie Copii Si Adolescenti

Timișoara, , Romania

Site Status RECRUITING

State Institution of Healthcare "Arkhangelsk Regional Clinical Psychiatric Hospital"

Arkhangelsk, , Russia

Site Status TERMINATED

Kazan State Medical University KSMU

Kazan', , Russia

Site Status SUSPENDED

SBHI Specialized Clinical Psychiatric Hospital 1

Krasnodar, , Russia

Site Status TERMINATED

Regional Public Institution "Lipetsk Regional Psychoneurological Hospital"

Lipetsk, , Russia

Site Status TERMINATED

Joint-Stock Company Scientific Centre of Personalized Medicine

Moscow, , Russia

Site Status TERMINATED

SBHI of Moscow Region "Central Clinical Psychiatric Hospital"

Moscow, , Russia

Site Status TERMINATED

Clinical Psychiatry Hospital #1 of Nizhniy Novgorod

Nizhny Novgorod, , Russia

Site Status TERMINATED

State Public Institution of Healthcare Leningrad Regional Psychoneurological Dispensary

Roshchino, , Russia

Site Status TERMINATED

Saint-Petersburg GUZ Psychiatric Hospital No.1 n.a. P.P. Kaschenko

Saint Petersburg, , Russia

Site Status TERMINATED

Federal State Budgetary Institution "National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev" of the Ministry of Healthcare of the Russian Federation

Saint Petersburg, , Russia

Site Status TERMINATED

Center for Medical Rehabilitation named after S.S. Mnukhin

Saint Petersburg, , Russia

Site Status TERMINATED

City Psychiatric Hospital #3 after I.I. Skvortsova-Stepanova

Saint Petersburg, , Russia

Site Status TERMINATED

GBUZ Samara Regional Clinical Psychiatric Hospital

Samara, , Russia

Site Status SUSPENDED

State Budgetary Healthcare Institution "Saratov City Clinical Hospital #2 n.a. V.I. Razumovsky"

Saratov, , Russia

Site Status TERMINATED

Smolensk State Medical University

Smolensk, , Russia

Site Status SUSPENDED

LLC Podderzhka

Stavropol, , Russia

Site Status TERMINATED

LLC Clinic "Sto Let"

Tomsk, , Russia

Site Status TERMINATED

Stavropol Regional Psychiatric hospital #2

Tonnel'nyy, , Russia

Site Status TERMINATED

Yaroslavl Regional Psychiatric Hospital

Yaroslavl Region, , Russia

Site Status TERMINATED

Clinic.Neuro.Psych.Child.Youth

Belgrade, , Serbia

Site Status TERMINATED

Institute for Mental Health

Belgrade, , Serbia

Site Status TERMINATED

Clinic for psychiatry, KCV

Novi Sad, , Serbia

Site Status RECRUITING

Regional Psychonevrological Hospital #3

Ivano-Frankivsk, , Ukraine

Site Status TERMINATED

SI "Institution of Neurology, Psychiatry and Narcology NAMS of Ukraine"

Kharkiv, , Ukraine

Site Status TERMINATED

State Institution "Institute of Health Care for Children and Adolescents of the AMS of Ukraine

Kharkiv, , Ukraine

Site Status TERMINATED

Kherson Regional Institution of Mental Care

Kherson, , Ukraine

Site Status TERMINATED

SI Research Institute of Psychiatry of MoH of Ukraine

Kyiv, , Ukraine

Site Status TERMINATED

Communal Institution of Lviv Regional Council Lviv Regional Clinical Psychiatric Hospital

Lviv, , Ukraine

Site Status TERMINATED

Odesa Regional Medical Centre of Mental Health

Odesa, , Ukraine

Site Status TERMINATED

Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I. Yushchenko"

Vinnytsia, , Ukraine

Site Status TERMINATED

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Colombia Mexico Romania Russia Serbia Ukraine

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Balázs Lázár

Role: CONTACT

+36 1 432 6437

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RGH-MD-20

Identifier Type: -

Identifier Source: org_study_id

2018-004006-26

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.